CARLSBAD, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch and completion of initial surgeries of the Mariner Adult Deformity Pedicle Screw System.
SeaSpine continues to build upon the strength and versatility of its foundational Mariner Pedicle Screw System to address the unique clinical requirements of complex adult deformity spine cases. This limited commercial launch adds advanced reduction and correction instrumentation, specialized implant technologies, and robust osteotomy tools to deliver efficient and powerful surgical intervention.
“The Mariner Adult Deformity System is the culmination of tireless collaboration between progressive clinical minds and SeaSpine’s innovative product development team,” stated Dennis Cirino, Senior Vice President, Global Spinal Systems. “Combined with 7D Flash Navigation, this system is designed to deliver a highly accurate and efficient workflow without the requirement for intraoperative radiation.”
The Mariner Adult Deformity System incorporates the strength of Mariner’s modular technology to provide a comprehensive implant offering while reducing the number of surgical trays typically associated with deformity surgery. This reduced physical footprint results in more seamless workflow, limited operating room clutter, and reduced sterile processing costs to the hospital. Furthermore, this system expands the differentiated capabilities of the Mariner Gimbal technology to enable more efficient placement of complex instrumentation.
Dr. Pawel Jankowski, neurosurgeon at Hoag Hospital, Newport Beach, CA, stated, “The Mariner Adult Deformity System delivers on the goal to make the treatment of challenging deformity cases easier and more efficient. The robust instrumentation and versatility of Mariner implants, combined with the capabilities of the 7D Flash Navigation System, result in an outstanding workflow in even the most complex surgeries.”
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to:
the ability of the Mariner Adult Deformity System to deliver efficient and powerful surgical intervention through advanced reduction and correction instrumentation, specialized implant technologies, and robust osteotomy tools; the ability of the Mariner Adult Deformity System, when combined with 7D Flash Navigation, to deliver a highly accurate and efficient workflow without the requirement for intraoperative radiation, to provide a more seamless workflow, limited operating room clutter, and reduced sterile processing costs to the hospital, and to expand the differentiated capabilities of the Mariner Gimbal technology to enable more efficient placement of complex instrumentation. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products, such as the Mariner Adult Deformity System, to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of substantial clinical validation of products following limited commercial (or “alpha”) launch; the fact that newly launched products may require substantial additional development activities, which could introduce further expense and delay, or as a result of delay in timely obtaining regulatory clearances; the Company’s ability to continue to invest in medical education and training for its newly launched products, including the Mariner Adult Deformity System; unexpected expense and delay, including as a result of developing and supporting the launch of new products; general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at
www.sec.gov
.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
[email protected]
